SCHEMBL1277680

SCHEMBL1277680

Cn1cc(Cl)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
CYP2C9 P11712 2/20 0.53
MEN1 O00255 2/20 0.53
POLB P06746 1/20 0.53
TDP1 Q9NUW8 1/20 0.45
RAB9A P51151 1/20 0.41
TPMT P51580 1/20 0.38
GRN P28799 2/20 0.36
SORT1 Q99523 2/20 0.36
GPR35 Q9HC97 1/20 0.36
MCL1 Q07820 1/20 0.36
KDM4E B2RXH2 1/20 0.36
RHEB Q15382 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 2/20 0.34
NOTUM Q6P988 1/20 0.34
GFER P55789 1/20 0.34
AR P10275 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674837 0.80 TDP1 (0.46) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL26333281 0.78 MEN1 (0.42) KMT2ACYP2C9MEN1POLBRAB9A
SCHEMBL1277233 0.78 CYP1A2 (0.56) KMT2AMEN1POLBRAB9AKDM4E
SCHEMBL26333287 0.76 MEN1 (0.41) KMT2ACYP2C9MEN1POLBRAB9A
SCHEMBL2783116 0.76 CYP2C9 (0.54) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL5174989 0.76 TDP1 (0.46) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL1441399 0.75 HDAC8 (0.47) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL781811 0.74 TDP1 (0.45) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL370476 0.74 TDP1 (0.45) KMT2ACYP2C9MEN1POLBTDP1
SCHEMBL25181069 0.74 KDM4E (0.52) KMT2ACYP2C9MEN1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405334-B1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2025-02-12 EP disclosed
US-20250002460-A1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2025-01-02 US disclosed
EP-4405334-A1 SORTILIN INHIBITORS Sortina Pharma AB (SE) 2024-07-31 EP disclosed
WO-2023101595-A1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2023-06-08 WO disclosed
WO-2023101595-A1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2023-06-08 WO disclosed
US-8349873-B2 Factor XA inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-01-08 US disclosed
US-20120088795-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-04-12 US disclosed
US-8063077-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-22 US disclosed
US-20110118244-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-19 US disclosed
US-20100249117-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2010-09-30 US disclosed
US-7767697-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-7763608-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-07-27 US disclosed
US-20090030045-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-01-29 US disclosed
EP-2016072-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-01-21 EP disclosed
WO-2007131179-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-11-15 WO disclosed
US-20070259924-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030045-A1 FACTOR XA INHIBITORS TFPI, F12, F11 KMT2A 3406/4885CYP2C9 37/4885MEN1 1444/4885
US-20110118244-A2 FACTOR XA INHIBITORS TFPI, F12, F11 KMT2A 3406/4885CYP2C9 37/4885MEN1 1444/4885
US-20100249117-A1 FACTOR XA INHIBITORS TFPI, F12, F11 KMT2A 3406/4885CYP2C9 37/4885MEN1 1444/4885
US-20250002460-A1 SORTILIN INHIBITORS SORT1, GRN, SCARB1 KMT2A 4849/4885CYP2C9 3124/4885MEN1 1086/4885
US-20070259924-A1 FACTOR XA INHIBITORS TFPI, F12, F11 KMT2A 3406/4885CYP2C9 37/4885MEN1 1444/4885
US-20120088795-A1 FACTOR XA INHIBITORS TFPI, F12, F11 KMT2A 3406/4885CYP2C9 37/4885MEN1 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.